An FDA advisory panel voted July 23–24, 2026, to recommend six of seven peptides for a government list that lets pharmacies mix these substances in bulk. If the FDA agrees, it would keep several popular peptide products on the market — products that currently live in a gray area because they have never gone through the FDA's standard drug approval process.

Peptides are short chains of amino acids, the building blocks of proteins. In medicine, they are sometimes used to signal the body to heal or repair tissue. Many are not FDA-approved drugs, but compounding pharmacies — which custom-mix medications rather than selling factory-made pills — still create and sell them. This is especially common in wellness, anti-aging, and sports medicine.

The committee reviewed seven peptides over the two-day meeting. Six received favorable votes: BPC-157, KPV, TB-500, MOTS-c, and two additional peptides not individually identified in the available reporting. The one the panel turned down was emideltide, which failed on a 7–6 vote against, with one abstention (Fierce Pharma).

Several of the favorable votes were close. BPC-157 passed on an 8–6 vote, as did KPV (STAT News). ABC News called the overall results a narrow endorsement (ABC News). The Washington Post, the most recently published source on the overall vote tallies, confirmed that six of seven peptides received the panel's recommendation (Washington Post).

BPC-157, one of the more widely recognized peptides in the compounding space, was proposed for the treatment of ulcerative conditions (Washington Post). KPV, TB-500, and MOTS-c were among the other peptides recommended for the compounding list (ABC News). The full identities of the remaining two recommended peptides were not specified in the available source reporting.

The meeting itself underwent scheduling adjustments before it convened. Originally announced on June 18, 2026, the session times were subsequently changed. The July 23 session, which began at 8:00 a.m. Eastern Time, had its end time extended from 4:30 p.m. to 6:20 p.m. Eastern (FDA). FDA published a meeting roster and a questions document for the morning session addressing whether certain substances should be reviewed for inclusion on the bulk compounding list (FDA roster; FDA questions document).

The panel's role is advisory — its votes do not change what pharmacies can do on their own. The recommendations go to the FDA, which makes the final call on which substances land on the official bulk compounding list under federal law. Think of it like a jury recommending a verdict: the judge still has to decide.

The broader context here is that the bulk substances list is the gateway. Substances on the list can be lawfully mixed in bulk by compounding pharmacies. Substances left off effectively lose that path. For compounding pharmacies, inclusion means continued access to the raw materials they need. For drug companies working on approved versions of similar peptides, inclusion means competing against products that have not been through the FDA's full review.

The close votes, especially the 8–6 results on BPC-157 and KPV, tell us the scientific evidence for these substances is genuinely disputed even among the experts on the panel. The emideltide rejection, with its 7–6–1 split, fits the same pattern. A divided panel gives the FDA more room to go its own way. The agency can accept, change, or reject the recommendations, and split votes historically give regulators more freedom to depart from what the committee suggested.

For anyone involved — pharmacies that supply these products, doctors who prescribe them through telehealth, and patients currently using them — the practical question is how quickly the FDA acts, and whether it accepts all six or picks and chooses given the narrow margins. Formal inclusion on the list would give these compounded peptide products a measure of stability they have not had so far. But if the FDA decides to go against the panel's advice, those products could lose their legal pathway.

No timeline for FDA's final decision on these substances was specified in the available reporting.